Today
Periodicals
Show Hide Related Items >> <<
04/15/21 Evelo Biosciences appoints Luca Scavo as CFO, Julie McHugh to board of directors 04/15/21 Merck to discontinue development of MRK-7110 in COVID-19 treatment 04/14/21 EMA says 'expediting' evaluation of Johnson & Johnson COVID-19 vaccine 04/13/21 J&J pauses vaccinations in all COVID-19 vaccine clinical trials 06:10 Today Ideaya Biosciences announces data from ongoing darovasertib, binimetinib trial 04/13/21 Pfizer can deliver 10% more vaccine doses to U.S. by end of May, says CEO 04/13/21 White House says J&J pause will not significantly impact vaccination plan 04/13/21 Moderna up 7% to $149.10 after CDC, FDA recommend pause in J&J vaccine use 04/14/21 Moderna says COVID-19 vaccine seen 90% effective against all cases at six months 04/14/21 Moderna says 14 different mRNA vaccine candidates entered into trials to date 04/14/21 Moderna sees Phase 1 study of mRNA flu vaccine candidate to begin in 2021 04/14/21 Moderna updates on clinical development of HIV vaccine candidates 07:12 Today AstraZeneca reports U.S. clearance of proposed acquisition of Alexion 04/14/21 Denmark to continue vaccine rollout without AstraZeneca COVID-19 vaccine 04/14/21 AstraZeneca's Tagrisso approved in China in early lung cancer 04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/14/21 Guggenheim Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim 04/13/21 Goldman Sachs J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs 04/13/21 Morgan Stanley Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers 04/13/21 JPMorgan Vaccine pause 'incremental negative' for J&J, says JPMorgan 04/13/21 Morgan Stanley Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers 04/13/21 JPMorgan Vaccine pause 'incremental negative' for J&J, says JPMorgan 04/09/21 Pfizer to host conference call 04/06/21 RBC Capital Pfizer transferred with a Sector Perform at RBC Capital 04/15/21 Piper Sandler Moderna price target raised to $234 from $208 at Piper Sandler 04/13/21 Morgan Stanley Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers 04/13/21 Piper Sandler Piper reiterates $208 target on Moderna after J&J Covid vaccine pause 04/07/21 Jefferies Catalent pact with Moderna removes potential overhang, says Jefferies 04/14/21 Guggenheim Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim 04/12/21 Fly Intel: Top five analyst downgrades 04/12/21 B. Riley B. Riley calls Agenus the next Seagen, reiterates $8 target 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 01/26/21 Johnson & Johnson sees FY21 adjusted operational EPS $9.25-$9.45 01/26/21 Johnson & Johnson reports Q4 adjusted EPS $1.86, consensus $1.82 01/25/21 Notable companies reporting before tomorrow's open 01/25/21 Notable companies reporting before tomorrow's open 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open 02/25/21 Moderna reports Q4 EPS (69c), consensus (35c) 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage
Recommendations
Jefferies analyst Saree…
Jefferies analyst Saree Boroditsky noted that Carlisle announced a price increase of up to 10% on its coatings and waterproofing products effective May 15, which follows a price increase announced earlier in the month on metal products ranging from 8%-30% effective May 3. Carlisle had previously implemented price increases on membranes and insulation and on metal products effective March 1, while competitor GAF has also been increasing prices, said Boroditsky, who also notes recent channel checks on the commercial roofing outlook for 2021 were positive. The analyst, who thinks Carlisle's guidance for the full year 2021 is likely conservative based on the multiple rounds of price increases and her recent channel checks, has a Buy rating and $180 price target on the shares.
Show Hide Related Items >> <<
02/12/21 Carlisle names Kelly P. Kamienski as Controller 02/02/21 Carlisle announces additional buyback of 5M shares of common stock 04/12/21 Oppenheimer Carlisle price target raised to $188 from $175 at Oppenheimer 04/12/21 Longbow Carlisle downgraded to Neutral from Buy at Longbow 03/25/21 Fly Intel: Top five analyst upgrades 03/25/21 Loop Capital Carlisle upgraded to Buy from Hold at Loop Capital 02/04/21 Carlisle reports Q4 EPS $1.57, consensus $1.16 10/20/20 Carlisle reports Q3 EPS $1.87, consensus $1.68
On The Fly
Check out this morning's…
Show Hide Related Items >> <<
03/09/21 State Street sees Q1 fee revenue growth better than previous guidance 02/18/21 State Street appoints Theresa McLaughlin as global CMO 01/20/21 State Street to eliminate 1,200 positions this year 01/19/21 State Street sees Q1 NII down about 68% sequentially 08:30 Today PPG says expects to complete the acquisitions of Tikkurila, Worwag during Q2 04/15/21 PPG sees broad-based global coatings demand 04/01/21 PPG opens China Application Innovation Center in Zhangjiagang 03/31/21 PPG announces paint agreement with Vizient 08:53 Today Morgan Stanley says investment banking pipelines 'healthy across products' 08:43 Today Morgan Stanley says Archegos exit 'money well spent' 08:39 Today Morgan Stanley says Q1 marked by 'numerous performance records' 04/15/21 Congress to host big bank CEOs for hearings the week of May 24 02/08/21 Editas Medicine appoints James Mullen as CEO 01/11/21 Editas Medicine Chief Scientific Officer Charles Albright, Ph.D to step down 01/11/21 Editas Medicine says FDA clears initiation of EDIT-301 clinical trial 12/21/20 Editas leads gene editing stocks higher with 46% rally to $95.42 04/08/21 Royalty Pharma acquires OXLUMO royalty interest from Dicerna for up to $240M 04/08/21 Royalty Pharma acquires Oxlumo royalty interest from Dicerna for $180M upfront 03/30/21 Dicerna announces data from preclinical studies of GalXC-Plus RNAi technology 03/04/21 Dicerna, Roche begin combo trial of GalXC for chronic HBV treatment 06:27 Today Citizens Financial CEO says 'confident' in outlook for balance of year 06:24 Today Citizens Financial reports Q1 net interest margin 2.76% vs. 3.10% a year ago 01/27/21 Citizens announces consumer financing partnership with BJ's Wholesale Club 01/20/21 Citizens Financial sees high single digit decrease in FY21 NIM 04/14/21 BNY Mellon chosen as transfer agent of Charles Schwab Investment Management 03/22/21 AFL-CIO teams with Wilmington Trust, BNY Mellon on retirement plan options 02/16/21 Amundi US appoints BNY Mellon as fund service provider 02/11/21 BNY Mellon announces formation of new digital assets unit 04/14/21 Denmark to continue vaccine rollout without AstraZeneca COVID-19 vaccine 04/14/21 AstraZeneca's Tagrisso approved in China in early lung cancer 04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 07:12 Today AstraZeneca reports U.S. clearance of proposed acquisition of Alexion 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 07:40 Today Ally Financial reports Q1 return on equity 21.7%, core ROTCE 24.1% 07:39 Today Ally Financial reports Q1 net interest margin 3.16%, up 50 bps y/y 03/11/21 CarLotz announces strategic relationship with Ally Financial 02/16/21 Soros buys Ally Financial, exits DraftKings in Q4 04/09/21 Deutsche Bank State Street price target raised to $100 from $97 at Deutsche Bank 04/07/21 Barclays State Street price target raised to $104 from $99 at Barclays 04/01/21 Wells Fargo State Street price target raised to $90 from $83 at Wells Fargo 04/01/21 Morgan Stanley State Street price target raised to $103 from $102 at Morgan Stanley 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink Alexion downgraded to Market Perform from Outperform at SVB Leerink 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 04:53 Today Goldman Sachs Dicerna initiated with a Buy at Goldman Sachs 03/18/21 Dicerna to hold a webinar on DCR-AUD disorder 03/02/21 H.C. Wainwright Dicerna price target raised to $40 from $35 at H.C. Wainwright EBET Esports Technologies $36.05 / +12.95 (+56.06%)
04/09/21 Jefferies Citizens Financial price target raised to $47 from $42 at Jefferies 04/07/21 Barclays Citizens Financial price target raised to $54 from $49 at Barclays 04/01/21 Deutsche Bank Citizens Financial price target raised to $50 from $44 at Deutsche Bank 03/30/21 Stephens Citizens Financial price target raised to $54 from $45 at Stephens 04/15/21 JPMorgan Ally Financial price target raised to $54 from $48 at JPMorgan 04/13/21 Wells Fargo Ally Financial price target raised to $57 from $51 at Wells Fargo 04/12/21 BofA Ally Financial reinstated with a Buy at BofA 04/08/21 Evercore ISI Ally Financial initiated with an Outperform at Evercore ISI 04/15/21 Citi Citi opens '30-day negative catalyst watch' on Axalta, PPG 04/07/21 Wells Fargo PPG price target raised to $173 from $165 at Wells Fargo 03/15/21 Credit Suisse PPG assumed with a Neutral at Credit Suisse 01/26/21 BofA PPG upgraded to Buy from Neutral at BofA 04/09/21 JMP Securities Goldman Sachs price target raised to $400 from $338 at JMP Securities 04/07/21 Barclays Morgan Stanley price target raised to $98 from $95 at Barclays 04/01/21 Deutsche Bank Morgan Stanley price target raised to $79 from $68 at Deutsche Bank 04/01/21 UBS Morgan Stanley price target raised to $92 from $84 at UBS 04/09/21 Deutsche Bank BNY Mellon price target raised to $54 from $50 at Deutsche Bank 04/07/21 Barclays BNY Mellon price target raised to $57 from $55 at Barclays 03/26/21 JPMorgan JPMorgan sees BNY Mellon, Wells Fargo among banks with most buyback capacity 03/24/21 Fly Intel: Top five analyst upgrades 04:56 Today Goldman Sachs Editas Medicine initiated with a Sell at Goldman Sachs 03/22/21 Credit Suisse Editas Medicine initiated with an Outperform at Credit Suisse 03/17/21 Guggenheim Editas Medicine assumed with a Neutral at Guggenheim 03/01/21 Barclays Editas Medicine downgraded to Equal Weight from Overweight at Barclays 04/14/21 Guggenheim Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim 04/12/21 Fly Intel: Top five analyst downgrades 04/12/21 B. Riley B. Riley calls Agenus the next Seagen, reiterates $8 target 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 07:44 Today State Street reports Q1 ex-items EPS $1.47, consensus $1.35 04/15/21 Notable companies reporting before tomorrow's open 01/19/21 State Street reports Q4 EPS $1.39, consensus $1.56 08:30 Today PPG sees Q2 adjusted EPS $2.15-$2.20, consensus $2.10 04/15/21 PPG reports Q1 EPS $1.88, consensus $1.56 04/15/21 Notable companies reporting after market close 01/22/21 PPG sees Q1 adjusted EPS $1.55-$1.61, consensus $1.89 07:34 Today Morgan Stanley reports Q1 EPS $2.19, consensus $1.70 04/14/21 Fly Intel: What to watch in next round of big bank earnings reports 02/25/21 Editas Medicine reports Q4 EPS ($1.00), consensus (74c) 11/05/20 Editas Medicine reports Q3 EPS 12c, consensus (64c) 02/25/21 Dicerna reports FY20 EPS ($1.52), consensus ($1.05) 11/05/20 Dicerna reports Q3 EPS (29c), consensus (20c) 06:23 Today Citizens Financial reports Q1 underlying EPS $1.41, consensus 97c 06:21 Today Citizens Financial reports Q1 underlying EPS $1.41, consensus 97c 06:34 Today BNY Mellon reports Q1 EPS 97c, consensus 87c 01/20/21 BNY Mellon reports Q4 ex-items EPS 96c, consensus 91c 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 07:37 Today Ally Financial reports Q1 adjusted EPS $2.09, consensus $1.15 01/22/21 Ally Financial reports Q4 adjusted EPS $1.60, consensus $1.05
Hot Stocks
AstraZeneca's (AZN)…
AstraZeneca's (AZN) proposed acquisition of Alexion Pharmaceuticals (ALXN) has "achieved an important step toward completion," having cleared U.S. Federal Trade Commission review following the conclusion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, the company announced. "The announcement follows competition clearances in Canada, Brazil, Russia and other countries globally, with a full list available on astrazeneca.com. Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan," AstraZeneca said.
Show Hide Related Items >> <<
04/14/21 Denmark to continue vaccine rollout without AstraZeneca COVID-19 vaccine 04/14/21 AstraZeneca's Tagrisso approved in China in early lung cancer 04/12/21 AstraZeneca's DARE-19 ph.3 trial of Farxiga in COVID-19 failed primary endpoint 04/09/21 AstraZeneca to unveil ARP1 selective inhibitor AZD5305 at AACR 03/26/21 Arcutis Biotherapeutics announces updates to its executive team 03/16/21 AstraZeneca withdraws FTC notification on Alexion deal, plans to refile 02/22/21 Arcturus Therapeutics acquires exclusive license from Alexion 02/16/21 Paulson & Co. buys Exxon, exits Qiagen in Q4 04/14/21 Guggenheim Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim 04/12/21 Fly Intel: Top five analyst downgrades 04/12/21 B. Riley B. Riley calls Agenus the next Seagen, reiterates $8 target 04/12/21 Argus AstraZeneca downgraded to Hold from Buy at Argus 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink Alexion downgraded to Market Perform from Outperform at SVB Leerink 02/04/21 Piper Sandler Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler 04/07/21 EMA says benefits of AstraZeneca Covid vaccine outweigh side effects 02/11/21 AstraZeneca sees FY21 core EPS $4.75-$5.00 02/11/21 AstraZeneca reports Q4 core EPS $1.07, total revenue $7.41B 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 02/04/21 Alexion reports Q4 EPS $2.96, consensus $2.56 10/29/20 Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95 10/29/20 Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60 04/15/21 Surgeon Gawande tells CNBC J&J vaccine pause should be lifted for older groups 04/14/21 EU to end AstraZeneca, J&J Covid vaccine contracts in 2022, Reuters says 04/09/21 AstraZeneca slashes vaccine deliveries to EU by 49%, FT reports 04/09/21 EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says 04/09/21 Fly Intel: Wall Street's top stories for Friday 04/09/21 Fly Intel: Wall Street's top stories at midday 04/07/21 Fly Intel: Wall Street's top stories for Wednesday 04/07/21 FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Fly Intel: Wall Street's top stories at midday 12/14/20 Fly Intel: Pre-market Movers 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 04/01/21 AstraZeneca put volume heavy and directionally bearish 03/22/21 AstraZeneca call volume above normal and directionally bullish 03/16/21 Unusually active option classes on open March 16th 02/24/21 AstraZeneca call volume above normal and directionally bullish 12/14/20 Early notable gainers among liquid option names on December 14th 10/20/20 Alexion call volume above normal and directionally bullish 10/19/20 Alexion call volume above normal and directionally bullish
Hot Stocks
Genentech, a member of…
Genentech, a member of the Roche Group, announced new Ocrevus analyses supporting its benefit on disease progression in early-stage relapsing-remitting multiple sclerosis, or RRMS, and primary progressive MS, or PPMS, as well as demonstrating persistence and adherence to twice-yearly dosing. These data are being presented virtually at the American Academy of Neurology, or AAN. Ocrevus is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 people have now been treated with Ocrevus globally. Ocrevus treatment provided consistent benefit over one year in patients who were recently diagnosed with RRMS and had not received prior disease modifying treatment, or DMT, in an interim analysis of open-label Phase IIIb study ENSEMBLE. After 48 weeks, 85% of Ocrevus-treated patients achieved no evidence of disease activity. The average annualized relapse rate across all patients was very low and their mean change in Expanded Disability Status Scale score, or EDSS, from baseline significantly improved from 1.71 to 1.55. Additionally, neurofilament light chain, or NfL, a marker of nerve cell damage, was reduced to nearly healthy control levels with Ocrevus treatment. The safety profile of Ocrevus in this trial was consistent with its overall favorable safety profile. Ocrevus treatment significantly slowed accumulation of atrophied T2-lesion volume, or aT2-LV, compared with placebo at 120 weeks in a post-hoc analysis of the ORATORIO study in PPMS. AT2-LV is a measure that reflects the volume of T2 lesions in brain tissue that is replaced by cerebrospinal fluid, and is believed to be a marker of disease progression in MS. People with PPMS experience three to five times higher accumulation of aT2-LV than people with relapsing MS and these data suggest that Ocrevus may favorably impact the underlying progressive biology of MS. Approximately 80% of patients adhered to twice-yearly dosing of Ocrevus after their second year of treatment compared with other DMTs, which were grouped by administration route, in a new analysis of U.S. commercial and insurance claims databases. Ocrevus also had the highest proportion of patients persist with therapy at two years. Ocrevus is approved in 95 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland, the United Kingdom and the EU.
Show Hide Related Items >> <<
04/15/21 Evelo Biosciences appoints Luca Scavo as CFO, Julie McHugh to board of directors 04/15/21 PTC Therapeutics announces FIREFISH trial results at AAN virtual meeting 04/13/21 Spark Therapeutics enters collaboration with Senti Biosciences 04/12/21 Roche announces FDA approval for Xolair prefilled syringe 04/12/21 B. Riley B. Riley calls Agenus the next Seagen, reiterates $8 target 03/29/21 RBC Capital PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation 03/25/21 Wedbush iTeos Therapeutics price target raised to $52 from $46 at Wedbush 03/23/21 Truist Truist sees mixed readthroughs to Wave's toplines from competitor HD setback 02/04/21 Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year 10/27/20 Oncolytics announces new GI cancer study using 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 02/11/21 Roche arthritis drug reduced Covid deaths in study, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 03/23/21 Fly Intel: Wall Street's top stories for Tuesday 03/23/21 Ionis Pharmaceuticals slides as Wall Street digests HD program setback 03/23/21 Fly Intel: Wall Street's top stories at midday 03/23/21 Fly Intel: Pre-market Movers
Yesterday
Hot Stocks
GlaxoSmithKline (GSK) and…
GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced that the European Medicines Agency, or EMA, has started a review of VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents aged 12 years and over and weighing at least 40 kg with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. The review is being carried out by the EMA's Committee for Human Medicinal Products, or CHMP, and will provide EU-wide recommendations for national authorities who may take evidence-based decisions on the early use of the medicine, ahead of any formal Marketing Authorization Application. "This week, the Australian Therapeutic Goods Administration (TGA), part of the Department of Health, granted VIR-7831 a provisional determination. VIR-7831 is the first anti-SARS-CoV-2 monoclonal antibody to have been granted this designation which provides a formal and transparent mechanism for accelerating the registration of promising new medicines with preliminary clinical data. VIR-7831 is an investigational compound and has not been granted a marketing authorisation anywhere in the world. An Emergency Use Authorization application for VIR-7831 has been submitted to the US Food and Drug Administration," the companies said.
Show Hide Related Items >> <<
04/08/21 Vir Biotechnology announces preclinical research on SARS-CoV-2 04/05/21 Vir Biotechnology announces preclinical research on VIR-7831 03/29/21 Eli Lilly, Vir, GSK announces topline data from Phase 2 BLAZE-4 trial 03/29/21 Eli Lilly, Vir Biotechnology, GlaxoSmithKline: Positive data from Phase 2 BLAZE 04/14/21 GlaxoSmithKline to stop enrolling patients in phase 2 feladilimab trial 04/12/21 Zentalis enters collaboration, supply agreement with GSK for ZN-c3 04/01/21 Lannett submits ANDA for generic equivalent of GlaxoSmithKline's Advair 04/01/21 Royalty Pharma acquires royalty interest in cabozantinib from GlaxoSmithKline 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink 03/08/21 JPMorgan JPMorgan double downgrades AnaptysBio back to Underweight after trial miss 03/11/21 Needham Vir Biotechnology price target raised to $80 from $75 at Needham 03/08/21 H.C. Wainwright Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright 03/03/21 Goldman Sachs Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs 03/03/21 H.C. Wainwright Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright 11/10/20 Vir Biotechnology reports Q3 EPS (67c), consensus (60c) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
Options
Unusual total active…
Unusual total active option classes on open include: Hewlett Packard Enterprise (HPE), GlaxoSmithKline (GSK), Inovio (INO), Melco Resorts (MLCO), Blackstone (BX), Virgin Galactic (SPCE), Taiwan Semi (TSM), C3 AI (AI), Visa (V), and DocuSign (DOCU).
Show Hide Related Items >> <<
03/29/21 Visa to settle transactions in USD Coin 03/22/21 Kaleyra announces agreement with Visa in Latin America, Caribbean 03/19/21 Visa drops 2% after WSJ says debit card practices under investigation 03/16/21 Visa appoints Michelle Gethers-Clark as Chief Diversity Officer 04/15/21 TSMC sees 2021 capital budget $30B 04/09/21 TSMC reports March revenue up 13.7% y/y to NT$129.13B 04/01/21 TSMC spending $100B over three years to 'keep up with demand' 03/10/21 TSMC reports February revenue NT$106.53B, up 14.1% y/y 04/15/21 Virgin Investments sells 5.58M share stake in Virgin Galactic for $150M 03/30/21 Virgin Galactic unveils first SpaceShip III VSS Imagine 03/05/21 Virgin Galactic down 7% after Palihapitiya sells 6.2M shares 02/25/21 Virgin Galactic CFO Jon Campagna to step down, Doug Ahrens to succeed MLCO Melco Resorts & Entertainment 04/01/21 Macau reports March casino revenue up 58.0% to 8.31B patacas 03/01/21 Macau reports February casino revenue up 135.6% to 7.31B patacas 02/25/21 Melco Resorts & Entertainment: Covid contnues to have material impact on ops 02/01/21 Macau reports January casino revenue down 63.7% to 8.02B patacas 04/15/21 Inovio's COVID-19 vaccine candidate shows response against all tested variants 03/01/21 Inovio reports REVEAL 1 trial met primary, secondary endpoints 02/24/21 Qiagen, Inovio expand collaboration to develop NGS companion diagnostic 02/23/21 Inovio doses first patient in Phase 1B clinical trial for INO-4500 04/12/21 DOE's LANL expands collaboration with HP Enterprise on new supercomputer design 03/31/21 HP Enterprise announces plan to add 150 new technologist jobs in Ireland 03/25/21 Meg Whitman, Mark Tatum join GM's Board of Directors 01/27/21 HP Enterprise to build $35M+ supercomputer for NCAR 04/14/21 GlaxoSmithKline to stop enrolling patients in phase 2 feladilimab trial 04/12/21 Zentalis enters collaboration, supply agreement with GSK for ZN-c3 04/01/21 Lannett submits ANDA for generic equivalent of GlaxoSmithKline's Advair 04/01/21 Royalty Pharma acquires royalty interest in cabozantinib from GlaxoSmithKline 04/08/21 DocuSign COO sells 5.8K shares of common stock 03/25/21 DocuSign sees FY22 operating margin at 13%-15%, long-term at 20%-25% 03/11/21 DocuSign falls 3% below $219 after Q4 results, FY22 guidance 02/11/21 DocuSign COO sells 5.8K shares of common stock 04/14/21 K Health, Blackstone Growth, Anthem to partner on technology joint venture 04/13/21 Blackstone to buy energy and telecom infrastructure provider Sabre Industries 03/25/21 Extended Stay America CEO calls acquisition transaction "compelling" 03/23/21 GeoComply announces Blackstone Growth, Atairos as first institutional investors 04/14/21 C3.ai rises 15.1% 04/08/21 C3.ai discloses Baker Hughes Holdings to sell 873.4K shares of common stock 03/08/21 C3.ai and Infor in pact to deliver scalable enterprise AI industry applications 03/02/21 C3.ai falls -14.0% 04/08/21 Morgan Stanley HP Enterprise price target raised to $17 from $15.50 at Morgan Stanley 03/26/21 JPMorgan HP Enterprise price target raised to $18 from $17 at JPMorgan 03/10/21 Fly Intel: Top five analyst upgrades 03/10/21 Daiwa HP Enterprise upgraded to Outperform from Neutral at Daiwa 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink 03/08/21 JPMorgan JPMorgan double downgrades AnaptysBio back to Underweight after trial miss 03/23/21 Fly Intel: Top five analyst initiations 03/23/21 BofA Inovio initiated with a Neutral at BofA 03/02/21 Piper Sandler Piper lowers Inovio target to $7 after 'decidedly negative' update 02/11/21 Oppenheimer Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target MLCO Melco Resorts & Entertainment 02/25/21 CLSA Melco Resorts & Entertainment upgraded to Outperform from Underperform at CLSA 01/07/21 Macquarie Melco Resorts & Entertainment downgraded to Neutral from Outperform at Macquarie 11/17/20 JPMorgan Melco Resorts & Entertainment price target raised to $25 from $23 at JPMorgan 11/05/20 Roth Capital Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30 04/12/21 Barclays Blackstone price target raised to $85 from $75 at Barclays 04/09/21 Deutsche Bank Blackstone price target raised to $66 from $61 at Deutsche Bank 03/19/21 Fly Intel: Top five analyst downgrades 03/18/21 Oppenheimer Blackstone downgraded to Perform on valuation at Oppenheimer 04/12/21 Bernstein Virgin Galactic initiated with a Market Perform at Bernstein 03/16/21 Truist Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target 03/16/21 Truist Virgin Galactic initiated with a Buy at Truist 03/03/21 BofA Virgin Galactic price target raised to $50 from $35 at BofA 04/12/21 Fly Intel: Top five analyst initiations 04/12/21 Atlantic Equities TSMC initiated with a Neutral at Atlantic Equities 04/01/21 DA Davidson Onto Innovation price target raised to $80 from $75 at DA Davidson 03/29/21 Citi TSMC recent selloff brings 'enhanced buying opportunity,' says Citi 03/02/21 Canaccord C3.ai price target lowered to $120 from $140 at Canaccord 01/04/21 KeyBanc C3.ai initiated with a Sector Weight at KeyBanc 01/04/21 Wedbush Wedbush bullish on C3.ai, initiates with an Outperform 01/04/21 Canaccord C3.ai initiated with a Hold at Canaccord 03/19/21 JPMorgan Visa has 'navigated heavy regulatory oversight' before, says JPMorgan 03/19/21 Wells Fargo Visa selloff on WSJ story likely a buying opportunity, says Wells Fargo 03/19/21 Barclays Visa, MasterCard facing new DOJ scrutiny on debt practices, says Barclays 03/16/21 Morgan Stanley Visa price target raised to $253 from $233 at Morgan Stanley 04/08/21 BofA BofA reinstates DocuSign at Buy with $250 price target 04/08/21 BofA DocuSign reinstated with a Buy at BofA 03/29/21 Daiwa DocuSign initiated with a Buy at Daiwa 03/25/21 DA Davidson DocuSign still confident in reaching $5B or more in revenue, says DA Davidson 01/28/21 Visa reports Q1 EPS $1.42, consensus $1.28 01/28/21 Notable companies reporting after market close 01/25/21 Fly Intel: What to watch in credit card space earnings reports 11/02/20 Fly Intel: What to watch in PayPal earnings report 04/15/21 TSMC sees Q2 revenue $12.9B-$13.2B, consensus $13.15B 04/15/21 TSMC reports Q1 EPS 96c, consensus 95c 01/14/21 TSMC sees Q1 revenue $12.7B-$13B, consensus $12.62B 01/14/21 TSMC reports Q4 EPS 97c, consensus 94c 02/25/21 Virgin Galactic reports Q4 EPS (31c) consensus (31c) 11/05/20 Virgin Galactic reports Q3 EPS (34c), consensus (26c) MLCO Melco Resorts & Entertainment 02/25/21 Melco Resorts & Entertainment reports Q4 EPS (42c), consensus (67c) 11/05/20 Melco Resorts & Entertainment reports Q3 EPS (70c), consensus (80c) 03/01/21 Inovio reports Q4 EPS (14c), consensus (22c) 11/09/20 Inovio reports Q3 EPS 11c, consensus (19c) 03/02/21 HP Enterprise raises FY21 adjusted EPS view to $1.70-$1.88, consensus $1.67 03/02/21 HP Enterprise sees Q2 adjusted EPS 38c-44c, consensus 38c 03/02/21 HP Enterprise reports Q1 adjusted EPS 52c, consensus 41c 12/01/20 HP Enterprise sees Q1 revenue down mid-single digits from Q4 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 03/11/21 DocuSign sees FY22 revenue $1.963B-$1.973B, consensus $1.89B 03/11/21 DocuSign sees Q1 revenue $432M-$436M, consensus $419.69M 03/11/21 DocuSign reports Q4 adjusted EPS 37c, consensus 22c 03/11/21 Notable companies reporting after market close 01/27/21 Blackstone reports Q4 distributable EPS $1.13, consensus 89c 01/26/21 Notable companies reporting before tomorrow's open 10/29/20 Blackstone reported Q3 distributable EPS 63c, consensus 57c (yesterday) 03/01/21 C3.ai reports Q3 EPS (13c), consensus (16c) 02/16/21 Tiger Global bought DoorDash and 1Life during Q4, sold out of Alphabet
Conference/Events
Horizons in Oncology…
Horizons in Oncology Virtual Conference to be held on April 15.
Show Hide Related Items >> <<
04/11/21 SQZ presents preclinical data on mRNA-based eAPCs, potential applicability 02/12/21 SQZ Biotechnologies falls -16.3% 02/12/21 SQZ Biotechnologies falls -13.1% 02/12/21 SQZ Biotechnologies falls -14.6% 04/07/21 Sesen Bio says independent proxy firms recommend voting for proposal 03/22/21 Sesen Bio, Qilu Pharmaceutical announce approval of Vicineum IND in China 03/08/21 Sesen Bio submits MAA to EMA for Vicineum 02/16/21 Sesen Bio announces FDA acceptance/priority review of Vicineum BLA 04/12/21 Oncolytics presents preclinical data on pelareorep at AACR 04/12/21 Oncolytics, SOLTI achieve primary endpoint in AWARE-1 study 02/23/21 Oncolytics announces publication of data from pelareorep and CAR T cells study 12/09/20 Oncolytics, SOLTI report data from AWARE-1 study of pelareorep 04/06/21 Olema Oncology appoints Yi Larson to board of directors 04/13/21 Pfizer can deliver 10% more vaccine doses to U.S. by end of May, says CEO 04/09/21 Pfizer, BioNTech seek expansion of vaccine EUA to include 12-15 year olds 04/01/21 Pfizer, BioNTech: Vaccine more than 91% effective after 6 months in study 03/31/21 BioNTech, Pfizer: 'Positive' results of COVID-19 vaccine study in adolescents 03/16/21 Aptose Biosciences appoints George Melko as VP, regulatory affairs 10/19/20 Aptose Biosciences initiates dosing of CG-806 in patients with AML 02/17/21 H.C. Wainwright Oncolytics initiated with a Buy at H.C. Wainwright 05/11/20 RBC Capital Oncolytics price target lowered to C$6 from C$9 at RBC Capital 02/17/21 Canaccord Sesen Bio price target raised to $7 from $5 at Canaccord 02/16/21 Canaccord Sesen Bio price target raised to $7 from $5 at Canaccord 02/16/21 Jefferies Jefferies doubles target on Sesen Bio to $6 on 'optimal scenario' 01/25/21 Canaccord Sesen Bio a must-own small cap for 2021, says Canaccord 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen 03/30/21 Brookline SQZ Biotechnologies initiated with a Buy at Brookline 01/07/21 Evercore ISI SQZ Biotechnologies initiated with an Outperform at Evercore ISI 11/24/20 Stifel SQZ Biotechnologies initiated with a Buy at Stifel 11/24/20 BofA SQZ Biotechnologies initiated with a Buy at BofA 02/22/21 JonesTrading Aptose Biosciences resumed with a Buy at JonesTrading 10/19/20 Cantor Fitzgerald Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald 09/22/20 Alliance Global Partners Aptose Biosciences initiated with a Buy at Alliance Global Partners 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 02/08/21 Jefferies Atreca initiated with a Buy at Jefferies 08/12/20 Stifel Volatility in Atreca shares creates 'interesting' opportunity, says Stifel 07/08/20 Piper Sandler Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler 07/01/20 Canaccord Atreca price target raised to $33 from $23 at Canaccord 02/23/21 B. Riley B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 03/15/21 Sesen Bio reports Q4 EPS (11c), consensus (11c) 11/09/20 Sesen Bio reports Q3 EPS (19c), consensus (8c) 10/27/20 Oncolytics announces new GI cancer study using 03/17/21 Olema Oncology reports Q4 EPS (50c), consensus (18c) 02/25/21 Atreca reports Q4 EPS (63c), consensus (64c) 11/12/20 Atreca reports Q3 EPS (66c), consensus (61c) 03/23/21 Aptose Biosciences reports Q4 EPS (17c), consensus (14c)
Hot Stocks
XOMA Corporation (XOMA)…
XOMA Corporation (XOMA) announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (AFMD) innate cell engager programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts. AFM13, which has Orphan Drug designation from the U.S. Food and Drug Administration, is a first-in-class CD30/CD16A ICE generated from Affimed's ROCK platform that induces specific and selective killing of CD30-positive tumor cells by engaging and activating natural killer cells and macrophages, thereby leveraging the power of the body's own innate immune system. Affimed currently is studying AFM13 in combination with cord blood-derived allogeneic natural killer cells in cooperation with the MD Anderson Cancer Center in Houston. AFM24 is a tetravalent, bispecific EGFR- and CD16A-binding ICE also generated from Affimed's ROCK platform. AFM24 uses the cytotoxic potential of the innate immune system by redirecting and activating NK cells and macrophages to kill EGFR-positive cancer cells through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, respectively. XOMA is eligible to receive undisclosed payments on future commercial sales of each of the three ICE molecules and any pre-loaded NK cells containing the ICE molecules. Additionally, XOMA is eligible to receive an undisclosed milestone for each program on achieving marketing approval.
Show Hide Related Items >> <<
03/23/21 Viracta Therapeutics, Xoma announce milestone, royalty monetization deal 03/10/21 Xoma expects cash to fund operations for multiple years 11/16/20 Xoma earns $2M milestone from Takeda Pharmaceutical 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement 04/14/21 Ridgeback Capital reports 5.5% passive stake in Affimed 04/12/21 Affimed highlights potential of Innate Cell Engager AFM24 at AACR 04/09/21 Affimed N.V. announces clinical data from cbNK cells with AFM13 study 03/31/21 Affimed N.V,'s IND application for antitumor combination granted FDA clearance. 01/19/21 H.C. Wainwright Xoma price target raised to $56 from $30 at H.C. Wainwright 04/12/21 BMO Capital Affimed price target raised to $15 from $12 at BMO Capital 03/30/21 Credit Suisse Affimed N.V. initiated with an Outperform at Credit Suisse 03/30/21 Credit Suisse Affimed N.V. initiated with an Outperform at Credit Suisse 03/24/21 Wells Fargo Affimed N.V. price target raised to $15 from $10 at Wells Fargo 03/10/21 Xoma reports Q4 EPS $1.32, two est. $2.00 11/05/20 Xoma reports Q3 EPS (10c), consensus (21c)